[PDF] Top 20 Percepción del paciente quirúrgico sobre la orientación proporcionada por la enfermera

... or metastatic breast cancer; 2) have HER2- negative disease, defined as an immunohistochemistry score of 0–1 + or have an immunohistochemistry score of 2 + and no gene amplification by ... See full document

... of patients, are in agreement with the clinical evidence reported in the literature and result in a recent and updated analysis of the survival data of the Phase III trial of nanoparticle ... See full document

... that nab- paclitaxel, an innovative formulation of albumin-bound paclitaxel, has a significant antitumor activity and a man- ageable safety profile in patients ... See full document

... breast and axillary lymph nodes (ypT0/isN0) was determined (Figure 3A and B). In CALGB 40603 sub-1, CALGB 40603 sub-2, CALGB 40603, and Bear et al study, a higher pCR rate in the BEV + CT group was not observed. ... See full document

... that nab-paclitaxel has sub- stantial activity and manageable toxicity as chemotherapy for breast cancer, and the outcome is better than with pacli- taxel formulated with CrEL, ... See full document

... the paclitaxel and m/z 859.5 → 291.1 for the d5- paclitaxel (internal ...for paclitaxel and d5-paclitaxel with a dwell time of 80 ms per ... See full document

... The normality of the distribution was checked using the univariate indices of skewness and kurtosis with an accep- tance threshold equal to 1. All variables complied with normality indices. Descriptive statistics were ... See full document

... 925 patients. Patients receiving nab-paclitaxel ...vs. paclitaxel had significantly longer TTD (median ...for patients with hormone receptor- positive/human epidermal growth ... See full document

... on chemotherapy and antiangiogenic ...first-line HER2-negative mBC setting are evaluating cancer immunotherapy agents, which have a different mode of action and thus may exhibit ... See full document

... at evaluation − value of marker at baseline)/value of marker at baseline × 100 – of both clinical markers was also used to identify the patients with increasing values and the ones with decreasing val- ues ... See full document

... A 65-year-old Caucasian woman, with a family history of BC, referred to our institution in May 2015 after casual check- ing of a lump in the left breast. Written informed consent of the patient and approval of ... See full document

... elderly patients remain ...elderly patients with NSCLC has yet to be fully ...Comprehensive Cancer Network for patients (all ages) with advanced NSCLC and PD-L1-positive and epidermal growth ... See full document

... and safety of paclitaxel. Nab-paclitaxel has also several advantages over CrEL-paclitaxel, such as no need for premedication, special infusion set with in-line filter and ... See full document

... of patients were with low, intermediate and high sTILs respectively compared to Denkert et al,2015 who reported that ...in patients’ characteristics were found between groups of sTILs IHC as regard age, ... See full document

... Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities ... See full document

... Therapeutic vaccine trials involving an array of recombinant constructs, peptides, proteins and whole tumor cells, all designed to prime circulating tumor specific T cells and attack PDAC, so far have reported ... See full document

... of breast cancer; whether it will prevent or delay the development of resis- tance; whether combination of ixabepilone with targeted therapies such as trastuzumab and bevacizumab will result in improved ... See full document

... Brain metastasis (BM) is very common in advanced non-small cell lung cancer (NSCLC) patients. The development of BM remains a serious complication associated with significant morbidity and mortality. The ... See full document

... weekly paclitaxel and carboplatin every 3 weeks was compared with the standard regimen of both paclitaxel and carboplatin every 3 weeks, in a study done by the Japanese Gynecologic Oncology ...dose-dense ... See full document

... in patients have shown that the addition of VDAs such as vadimezan or fosbretabulin to standard chemotherapy is well tolerated and appears to produce a higher RR in the populations studied to ... See full document